Kodama N, Furuse K, Kawahara M, Arai R, Tsuruta S, Hayashi S, Kiyota T
Gan To Kagaku Ryoho. 1987 Jan;14(1):159-64.
The present trial was designed to compare the effect of metoclopramide(MCP) + dexamethasone(DM) (Method A) with that of MCP + DM + lorazepam(Lor) (Method B) in the treatment of CDDP (cis-diamminedichloroplatinum)-induced nausea and vomiting in a randomized fashion. The results were collected by questionnaire given to 50 patients. The dosage of CDDP was 80-100 mg/m2. In addition, MMC and VDS, or VP-16 were used concurrently. Within 24 hours after the administration of CDDP, vomiting was not observed in 72% and 88% of the patients treated with Method A and Method B, respectively, and nausea was not noted in 48% and 68%, respectively. Marked malaise was observed in 36% of patients in the Method A group and in 12% in the Method B group. With respect to the extent of comfort, 16% of patients in the Method A group and 56% in the Method B group felt good. Sixteen percent in the Method A group and 56% in the Method B group were satisfied with the anti-emetic treatment. Thus, Method B was significantly superior to Method A with regard to the degree of comfort and treatment satisfaction.
本试验旨在随机比较胃复安（MCP）+地塞米松（DM）（方法A）与MCP+DM+劳拉西泮（Lor）（方法B）治疗顺铂（顺二氨二氯铂）引起的恶心和呕吐的效果。通过对50例患者进行问卷调查收集结果。顺铂的剂量为80-100mg/m²。此外，同时使用丝裂霉素（MMC）和长春地辛（VDS）或依托泊苷（VP-16）。在给予顺铂后的24小时内，方法A和方法B治疗的患者中分别有72%和88%未观察到呕吐，分别有48%和68%未出现恶心。方法A组36%的患者和方法B组12%的患者出现明显不适。在舒适度方面，方法A组16%的患者和方法B组56%的患者感觉良好。方法A组16%的患者和方法B组56%的患者对止吐治疗满意。因此，在舒适度和治疗满意度方面，方法B明显优于方法A。
